股票代码：301069 信息披露义务人：华邦生命健康股份有限公司 住所及通讯地址：重庆市渝北区人和星光大道 69 号 股份变动性质：本次权益变动的方式系信息披露义务人华邦健康发行可交换 债持有人换股导致持股比例降低。 简式权益变动报告书签署日期：2025 年 10 月 28 日 山东凯盛新材料股份有限公司 简式权益变动报告书 上市公司名称：山东凯盛新材料股份有限公司 股票上市地点：深圳证券交易所 股票简称：凯盛新材 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购办法》"）、《公开发行证券的公司 信息披露内容与格式准则第 15 号——权益变动报告书》（以下简称"准则 15 号"） 及相关的法律、法规编写本报告书。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 三、依据《证券法》《收购办法》及准则 15 号的规定，本报告书已全面披露 了信息披露义务人在山东凯盛新材料股份有限公司中拥有权益的股份变动情况。 四、截至本报告书签署之日，除本报告书披 ...

Core Viewpoint - The company has reported an improvement in the yield rate of its PEKK products and is progressing with market expansion as planned [1] Group 1 - The yield rate of PEKK products has been continuously improving this year [1] - Market development is proceeding according to the company's plans [1]

Group 1 - The core point of the article is that Kaisheng New Materials (301069.SZ) has begun supplying high-purity battery-grade thionyl chloride to relevant production enterprises [1] Group 2 - The company has made a significant step in its production capabilities by providing a specialized chemical product for the battery industry [1]

Core Viewpoint - The company has reported an improvement in the yield rate of its PEKK products and is progressing with market expansion as planned [1] Group 1 - The yield rate of PEKK products has been continuously improving this year [1] - Market development is proceeding according to the company's plans [1]

Core Viewpoint - The company, Kaisheng New Materials, has successfully supplied high-purity battery-grade thionyl chloride to relevant production enterprises [1] Group 1 - The company announced on October 28 that it has begun supplying high-purity battery-grade thionyl chloride [1]

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-045 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例触及1%整数倍的公告 1.本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司"或 "本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发行 的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简称 "25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券持 有人换股，导致控股股东持股比例被动从 36.44%减少至 35.88%，权益变动触及 1%的整数倍。 2.本次权益变动不触及要约收购，不会导致公司控股股东或实际控制人发生 变化，亦不会对公司治理结构及持续经营产生重大影响。 一、控股股东可交换公司债券的基本情况 华邦健康于 2025 年 4 月 22 日面向专业投资者非公开发行可交换公司债券 （以下简称"本期可交换债券"），并于 2025 年 4 月 28 日起在深 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 774 million yuan for the first three quarters of 2025, representing a year-on-year growth of 11.22%, and a net profit attributable to shareholders of 116 million yuan, up 121.56% year-on-year [5][6] - In Q3 2025, the company achieved a revenue of 242 million yuan, a year-on-year increase of 19.96%, but a quarter-on-quarter decrease of 8.21% [5] - The demand for chlorosulfonic acid and intermediates was weak in the off-season, leading to a narrowing of price spreads, while the aramid monomer business remained stable [6] - The company is set to increase production of PEKK, a high-value material, which is crucial for national strategic development and industrial upgrading [7] - The company has successfully implemented a one-step production method for PEKK, providing a significant cost advantage over the two-step method used by foreign competitors [7] - The company is expanding its product line and has made significant progress in the development of new products, which are expected to support future growth [8] Financial Summary - For 2025, the company is projected to achieve a net profit of 145 million yuan, with corresponding P/E ratios of 69 times [12] - Revenue is expected to grow from 928 million yuan in 2024 to 1614 million yuan in 2027, with a compound annual growth rate of 17.7% [12] - The gross profit margin is anticipated to improve from 23% in 2024 to 31.2% in 2027 [12] - The return on equity (ROE) is expected to rise from 3.4% in 2024 to 11.9% in 2027 [12]

| 证券代码：301069 | 证券简称：凯盛新材 | 公告编号：2025-044 | | --- | --- | --- | | 债券代码：123233 | 债券简称：凯盛转债 | | 山东凯盛新材料股份有限公司 关于控股股东非公开发行可交换公司债券换股进展 暨权益变动比例超过1%的公告 公司控股股东华邦生命健康股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致， 并保证披露的公司相关信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 重要提示： 1.本次权益变动主要系山东凯盛新材料股份有限公司（以下简称"公司"或 "本公司"）控股股东华邦生命健康股份有限公司(以下简称"华邦健康")发行 的华邦健康 2025 年面向专业机构投资者非公开发行可交换公司债券（债券简称 "25 华邦 EB"，债券代码"117227"，以下简称"本次可交换债券"）的债券持 有人换股，导致控股股东持股比例被动从 39.75%减少至 36.44%。 2.本次权益变动不触及要约收购，不会导致公司控股股东或实际控制人 ...

Market Overview - On October 23, the chemical raw materials sector rose by 1.17%, with Shilong Industrial leading the gains [1] - The Shanghai Composite Index closed at 3922.41, up 0.22%, while the Shenzhen Component Index closed at 13025.45, also up 0.22% [1] Top Performers - Shilong Industrial (002748) closed at 13.98, up 9.99% with a trading volume of 286,600 shares and a transaction value of 394 million [1] - Kaisheng New Materials (301069) closed at 25.02, up 6.97% with a trading volume of 348,800 shares [1] - Zhongyida (600610) closed at 12.15, up 4.83% with a trading volume of 879,500 shares [1] Underperformers - Sanqi Co. (603938) saw a decline of 10.00%, closing at 17.73 with a trading volume of 326,900 shares and a transaction value of 589 million [2] - Chiyanjingshen (663299) decreased by 6.17%, closing at 11.56 with a trading volume of 378,800 shares [2] - Hengguang Co. (301118) fell by 3.88%, closing at 25.00 with a trading volume of 54,400 shares [2] Capital Flow - The chemical raw materials sector experienced a net outflow of 48.83 million from institutional investors, while retail investors saw a net inflow of 205 million [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors are more active [2] Individual Stock Capital Flow - Zhongyida (600610) had a net inflow of 103 million from institutional investors, while retail investors showed a net outflow of approximately 97 million [3] - Shilong Industrial (002748) recorded a net inflow of 31.81 million from institutional investors, with retail investors also showing a net outflow [3] - Kaisheng New Materials (301069) had a net inflow of 52.49 million from institutional investors, while retail investors experienced a net outflow of about 49.64 million [3]

Group 1 - The core viewpoint of the news is that Kaisheng New Materials has experienced a decline in stock price recently despite a significant increase in its stock price year-to-date [1][2] - As of October 23, the stock price of Kaisheng New Materials was 22.92 CNY per share, with a market capitalization of 9.641 billion CNY [1] - The company has seen a net outflow of main funds amounting to 6.0233 million CNY, with large orders showing a higher selling volume compared to buying [1] Group 2 - Year-to-date, Kaisheng New Materials' stock price has increased by 55.18%, but it has seen a slight decline of 0.43% over the last five trading days and a 3.90% decline over the last 20 days [2] - The company reported a revenue of 774 million CNY for the period from January to September 2025, representing a year-on-year growth of 11.22%, and a net profit of 116 million CNY, which is a significant increase of 121.56% year-on-year [2] - The main business revenue composition includes carboxylic chlorides (59.25%), inorganic chemicals (26.23%), and hydroxyl chlorides (13.93%) [2] Group 3 - Since its A-share listing, Kaisheng New Materials has distributed a total of 273 million CNY in dividends, with 168 million CNY distributed over the past three years [3] - As of September 30, 2025, the number of shareholders decreased by 4.54% to 31,400, while the average circulating shares per person increased by 4.55% to 12,468 shares [2][3] - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited holds 2.6049 million shares, a decrease of 647,300 shares compared to the previous period [3]